Pre-made Cofetuzumab biosimilar ( Whole mAb ADC, anti-PTK7 therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-115
Anti-PTK7 therapeutic antibody (Pre-made Cofetuzumab biosimilar,Whole mAb ADC) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Cofetuzumab pelidotin (INN; development code PF-06647020) is an experimental antibody-drug conjugate in development for the treatment of cancer. It was created by Stemcentrx and is being developed by Pfizer. The drug is an anti-PTK7 monoclonal antibody linked to auristatin-0101, an auristatin microtubule inhibitor.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-PTK7 therapeutic antibody (Pre-made Cofetuzumab biosimilar,Whole mAb ADC)|
|Format||Whole mAb ADC|
|Highest_Clin_Trial (Jan '20)||Phase-I|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Conditions Active||Non-small cell lung cancer;Solid tumours|
|Conditions Discontinued||Breast cancer|